



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### **The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells.**

**Citation for published version:**

Chan, WI, Hannah, RL, Dawson, MA, Pridans, C, Foster, D, Joshi, A, Gottgens, B, Van Deursen, JM & Huntly, BJP 2011, 'The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells.', *Molecular and Cellular Biology*, vol. 31, no. 24, pp. 5046-5060.  
<https://doi.org/10.1128/MCB.05830-11>

**Digital Object Identifier (DOI):**

[10.1128/MCB.05830-11](https://doi.org/10.1128/MCB.05830-11)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

Molecular and Cellular Biology

**Publisher Rights Statement:**

Copyright © 2011, American Society for Microbiology. All Rights Reserved.

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



## The Transcriptional Coactivator Cbp Regulates Self-Renewal and Differentiation in Adult Hematopoietic Stem Cells<sup>▽</sup>

Wai-In Chan,<sup>1</sup> Rebecca L. Hannah,<sup>1</sup> Mark A. Dawson,<sup>1</sup> Clare Pridans,<sup>1†</sup> Donna Foster,<sup>1</sup>  
Anagha Joshi,<sup>1</sup> Berthold Göttgens,<sup>1</sup> Jan M. Van Deursen,<sup>2</sup> and Brian J. P. Huntly<sup>1,3\*</sup>

Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Hills Road, Cambridge CB2 0XY, United Kingdom<sup>1</sup>; Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905<sup>2</sup>; and Cambridge University Foundation Hospital Trust, Hills Road, Cambridge CB2 2QQ, United Kingdom<sup>3</sup>

Received 20 June 2011/Returned for modification 30 July 2011/Accepted 9 October 2011

**The transcriptional coactivator Cbp plays an important role in a wide range of cellular processes, including proliferation, differentiation, and apoptosis. Although studies have shown its requirement for hematopoietic stem cell (HSC) development, its role in adult HSC maintenance, as well as the cellular and molecular mechanisms underlying Cbp function, is not clear. Here, we demonstrate a gradual loss of phenotypic HSCs and differentiation defects following conditional ablation of *Cbp* during adult homeostasis. In addition, *Cbp*-deficient HSCs reconstituted hematopoiesis with lower efficiency than their wild-type counterparts, and this response was readily exhausted under replicative stress. This phenotype relates to an alteration in cellular fate decisions for HSCs, with *Cbp* loss leading to an increase in differentiation, quiescence, and apoptosis. Genome-wide analyses of Cbp occupancy and differential gene expression upon *Cbp* deletion identified HSC-specific genes regulated by *Cbp*, providing a molecular basis for the phenotype. Finally, Cbp binding significantly overlapped at genes combinatorially bound by 7 major hematopoietic transcriptional regulators, linking Cbp to a critical HSC transcriptional regulatory network. Our data demonstrate that *Cbp* plays a role in adult HSC homeostasis by maintaining the balance between different HSC fate decisions, and our findings identify a putative HSC-specific transcriptional network coordinated by Cbp.**

The cyclic AMP response element binding protein (CREB)-binding protein (CREBBP; here, CBP or Cbp) and its paralogue, p300, are large multidomain proteins with transcriptional coactivator properties that participate in numerous cellular processes during development and homeostasis (10). They modulate locus-specific transcription by a number of separate mechanisms, including their direct catalytic activity, which can acetylate both histone (2) and nonhistone (11) proteins, as well as through multiple protein-protein interactions with transcription factors, chromatin-remodeling complexes, and the basal transcriptional machinery (3). Furthermore, through interaction with multiple components within wider transcriptional networks, Cbp/p300 may further integrate and orchestrate whole transcriptional programs.

Precise temporal and spatial control of specific transcriptional programs is required for the development, maintenance, and differentiation of organ systems. Strong evidence has linked *Cbp* function with both normal and malignant hematopoiesis. *Cbp* and *p300* have been demonstrated to have tumor suppressor roles in the development of hematological malignancies in mice (18, 23). Germ line mutations of *CBP* occur in the cancer predisposition syndrome Rubinstein-Taybi syndrome (35). *CBP* is also the direct target of chromosomal

translocations associated with acute myeloid leukemia (AML), for which its C terminus is fused to the chromatin modifiers *MLL* (*MLL1*) and *MOZ* (*MYST3*) (7, 39). Previous studies have shown that *Cbp* and *p300* functions are required for early embryonic development as well as hematopoietic stem cell (HSC) specification. Homozygous loss of either *Cbp* or *p300* leads to embryonic lethality between embryonic day 9 (E9) and E11.5 due to defects in neurulation and other proliferative defects (23, 29, 30, 41, 47). *Cbp*<sup>−/−</sup> embryos exhibit pallor and demonstrate defects in primitive hematopoiesis (30). Furthermore, *Cbp*<sup>−/−</sup> embryonic stem (ES) cells contributed significantly to other tissues but failed to generate any hematopoietic changes in chimeric animals (34). Studies of *Cbp* and *p300* heterozygous mice, where one allele of *Cbp* is already lost in developing HSCs and in other tissues, have suggested differential roles for the paralogues: for *Cbp* in HSC self-renewal and for *p300* in hematopoietic differentiation during early development (34). Studies have shown that some transcription factors, such as Runx1, that are critical during early-stage hematopoiesis become dispensable in adult HSC maintenance (16). Although studies of adult mice have demonstrated the importance of *Cbp* and *p300* for B- and T-cell development (19, 46), no studies have demonstrated the consequences of *Cbp* deficiency in normal adult HSC maintenance and function. A recent study also suggested a potential role for *Cbp* in the hematopoietic microenvironment (53). Despite all these studies, the cellular mechanisms as well as the hematopoietic transcriptional network by which *Cbp* regulates hematopoiesis and adult HSC function have not been addressed. Here, using functional studies of a *Cbp* conditional knockout mouse model together with integrated genomic analyses, we demonstrate

\* Corresponding author. Mailing address: Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Hills Road, Cambridge CB2 0XY, United Kingdom. Phone: 44-1223-331153. Fax: 44-1223-762670. E-mail: bjph2@cam.ac.uk.

† Present address: The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Roslin, Midlothian EH25 9PS, United Kingdom.

<sup>▽</sup> Published ahead of print on 17 October 2011.

that *Cbp* regulates HSC quiescence, apoptosis, and differentiation, and we identify putative hematopoietic transcriptional networks coordinated by *Cbp*.

## MATERIALS AND METHODS

**Mice.** *Cbp* conditional knockout mice (18) were bred with Mx-Cre transgenic mice (22), both on the C57BL/6 background. To induce Cre-mediated recombination, 6- to 10-week-old mice were administered 5 doses of poly(I) · poly(C) (300 µg per dose; Sigma) by intraperitoneal injection every other day over 10 days. Deletion efficiency was determined by PCR of genomic DNA extracted from various tissues. Peripheral blood (PB) samples were taken from the lateral saphenous vein and collected in EDTA-treated tubes (Sarstedt, Germany). Automated total and differential blood cells were counted using a Vet abc automated counter (Scil Animal Care, Viernheim, Germany). All mice were housed in a pathogen-free animal facility. Experiments were conducted under UK Home Office regulations.

**Flow cytometry analysis.** Single-cell suspensions of bone marrow (BM) cells were prepared by flushing both femurs and tibiae and by obtaining spleen cells, with cell populations homogenized with Dulbecco's phosphate-buffered saline (DPBS; Invitrogen) supplemented with 2% fetal bovine serum (FBS; Sigma). Cells were filtered through a 70-µm nylon cell strainer (BD Biosciences). All BM, spleen, and PB samples were treated with red blood cell lysis buffer (5 PRIME, Germany) prior to the subsequent experiments. Cell numbers were determined using a CASY cell counter (Schärfe System GmbH, Germany). All staining was performed in DPBS with 0.1% bovine serum albumin and 1 mM EDTA. Antibodies used were as follows: affinity-purified rat anti-mouse lineage markers CD4, CD45R, LY-6C/G, TER119, CD19, and CD8a (all from Invitrogen) and CD3 (17A2; BD Biosciences). Other surface markers were as follows: from BD Biosciences, c-Kit (2B8; phycoerythrin [PE] conjugated), CD45.1 (A20; PE conjugated), CD45.2 (104; fluorescein isothiocyanate [FITC] conjugated), and CD4 (RM4-5; PE-Cy7 conjugated); from eBioscience, CD127 (interleukin-7 receptor  $\alpha$  [IL-7R $\alpha$ ]; A7R34; biotin conjugated), CD135 (Flk-2/flt-3; A2F10; biotin conjugated), CD16/32 (93; biotin conjugated), CD34 (RAM34; FITC conjugated), Ly-6G (Grl; PE-Cy7 conjugated), CD3 (PE-Cy7 conjugated), CD11b (M1/70; allophycocyanin [APC] conjugated), and streptavidin-PE-Cy7 conjugated secondary antibody; from Invitrogen, Ly-6A/E (Sca-1, D7; Alexa Fluor 647 conjugated), CD45R (APC conjugated), and Pacific blue anti-mouse IgG F(AB')<sub>2</sub> fragments. Flow cytometry analysis was performed on a CyAn ADP flow cytometer (Dako). All data were analyzed with FlowJo software (Tree Star, Inc.).

**Isolation of the LSK population by flow sorting.** BM cells were harvested from femurs and tibiae from mice with the same genotype at 4 weeks after poly(I) · poly(C) treatment. BM cells were first stained with affinity-purified rat anti-mouse lineage markers (CD4, CD3, CD45R, LY-6C/G, TER119, CD19, and CD8a [listed above]). Lineage-positive cells were depleted using Dynabeads (sheep anti-rat IgG; Invitrogen) according to the manufacturer's instructions. Lineage-depleted BM cells were labeled with c-Kit PE-conjugated (BD Biosciences) and Sca-1 Alexa Fluor 647-conjugated (Invitrogen) antibodies. 7-Aminoactinomycin D (7-AAD) was added to exclude dead cells. The LSK population (Lin<sup>−</sup> c-Kit<sup>hi</sup> Sca-1<sup>hi</sup>) was sorted using a MoFlo cell sorter (Beckman Coulter).

**Cell cycle and apoptosis analyses.** Mice were injected intraperitoneally with 1 mg of bromodeoxyuridine (BrdU; BD Biosciences). BM cells were collected 24 h later and stained with surface markers as stated above prior to BrdU detection, following the manufacturer's instructions (BrdU flow kit; BD Biosciences). For 5-fluorouracil (5-FU) treatment, 1 dose of 5-FU was injected intraperitoneally at a dose of 150 mg/kg of body weight. BM cells were collected 10 days later for fluorescence-activated cell sorting (FACS) analysis. The Ki-67 staining procedure was similar to that for BrdU detection, except a Ki-67-FITC antibody (BD Biosciences) was used without DNase treatment. Annexin V-FITC staining (Miltenyi Biotec) was performed according to the manufacturer's instructions. DNA content was labeled with 7-AAD (BD Biosciences).

**Bone marrow transplantation assays.** Unfractionated BM cells from 6- to 10-week-old *Cbp* Mx or *Cbp* wild-type (wt) littermates (CD45.2) were collected as donor cells 4 weeks after poly(I) · poly(C) treatment. For competitive transplantations, these cells were mixed with competitor BM cells (CD45.1) at different ratios (1:1 and 3:1). A total of  $1 \times 10^6$  cells were injected intravenously into lethally irradiated (550 rads; 2 doses) C57BL/6 recipients (CD45.1/45.2). For the serial transplantation experiment,  $1 \times 10^6$  donor cells (CD45.2) were injected intravenously into lethally irradiated (550 rads; 2 doses) C57BL/6 recipients (CD45.1). At 16 weeks after the primary transplantation,  $1 \times 10^6$  unfractionated BM cells from the primary recipients were pooled and injected into the second-

ary recipients. The whole procedure was repeated for the tertiary transplantation. PB chimerism was monitored by flow cytometry analysis monthly. Reconstitution of BM cells in the primary, secondary, and tertiary recipients was assessed at 16 weeks posttransplantation.

**Homing assay.** Whole BM cells were collected from *Cbp* wt or *Cbp* Mx mice 4 weeks after poly(I) · poly(C) treatment. Single cells were labeled using a Vybrant carboxyfluorescein diacetate succinimidyl ester (CFDA SE [CFSE]) cell tracer kit (Invitrogen) for 15 min at 37°C. BM cells were washed in DPBS (Invitrogen) to remove excess dye. A total of 5 million labeled BM cells were transplanted into lethally irradiated recipients (CD45.1). BM cells from recipients were collected 24 h after transplantation. CFSE-positive stem and progenitor populations were assessed by flow cytometry.

**Microarray analysis.** Total RNA was extracted from pooled sorted LSK cells by using TRIzol reagent (Invitrogen) and a standard protocol. Five nanograms of RNA was amplified using the Ovation RNA amplification system V2 (NuGEN) and labeled with biotin. The biotin-labeled cDNA samples were then hybridized onto the Illumina mouse WG-6 v2 bead chip array, following the manufacturer's instructions. Probe selection was performed using the R package Lumi (9). Probes that were successfully detected over background (*P* values of <0.01 in Lumi) in at least one sample were selected for subsequent analyses. Data were transformed using variance stabilization followed by normalization using quantile normalization (25). The comparisons in expression levels between samples were performed using the R package Limma. Probes differentially expressed (*P* values of <0.05) were selected for subsequent analyses.

**GSEA.** Gene set enrichment analysis (GSEA) software and all curated gene sets (c2.All.v3.0.symbols.gmt) were obtained from the GSEA website (<http://www.broadinstitute.org/gsea/index.jsp>) (37). Gene enrichment analyses were performed using the default settings.

**Chromatin immunoprecipitation and sequencing assay (ChIP-seq) and data analysis.** HPC-BM cells (33) were maintained in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% FBS, monothioglycerol (MTG; Sigma), 100 ng/ml of stem cell factor, and 10 ng/ml of human IL-6. Cells were cross-linked with 1% formaldehyde. Immunoprecipitation was performed using rabbit polyclonal Cbp antibody (ab2832; Abcam) and rabbit IgG antibody (Abcam) as a negative control as described previously (8). Each sample was amplified and sequenced using an Illumina Genome Analyzer IIx. All sequencing reads for each sample were converted into density maps (.wig files). Peak calling was performed using the peak-finding program MACS (model-based analysis of ChIP-Seq) (52) as described in reference 45 with the following modified command line parameters for MACS: mfold, 16; *t* size, 35; bw, 100; *P* =  $1e-5$ ; gsize, 1,870,000,000; no lambda. All peaks were standardized to be 400 bp wide. Data were mapped to mouse reference genome (mm9) and displayed as UCSC genome browser custom tracks. For gene mapping and peak distribution analysis, genes were mapped to peaks by examining a 100-kb region around each peak and linking the nearest 3' and 5' genes to that peak. If a gene had a transcription start site within 1,000 bp from the peak, then only that gene was considered. Peak coordinates were checked for overlap with genes. If a peak overlapped 1,000 bp upstream of a gene, it was assigned as a promoter peak. The remaining peaks were either assigned as intragenic, if overlapping a gene by at least 1 bp, or intergenic, if not overlapping a gene or promoter region. The motif-finding program MEME (1) was used to find overrepresented motifs in three groups of peaks with the following parameters: -dna -nmotifs, 20; -evt, 0.01; -maxsize, 1,000,000. The middle 100 bp was taken for all peak regions, and peaks were excluded from analysis if they had more than 40% of repetitive sequence. The motif comparison tool TOMTOM (12) was then used to identify the motifs found by MEME.

**Quantitative real-time PCR.** For gene expression analysis, RNA from flow-sorted LSK cells was extracted using TRIzol reagent (Invitrogen) following the standard protocol. cDNA was synthesized using a SuperScript VILO cDNA synthesis kit (Invitrogen) following the manufacturer's instructions. Quantitative reverse transcription-PCR (qRT-PCR) was carried out with SYBR green PCR master mix in the ABI Prism 7000 system (Applied Biosystems). The expression level of RNA was calculated using the standard curve method, normalized to the expression of  $\beta$ -actin. Results were from 2 individual PCRs from 3 individual samples. For ChIP-PCR, genomic DNA immunoprecipitated with the Cbp or rabbit IgG antibody was subjected to real-time PCR as described above. Input DNA was used to generate a standard curve. Enrichment of binding at particular genomic loci is presented as the percentage of the input DNA. All PCR results were from two individual experiments. Primer sequences are available upon request.

**Statistical analysis.** An unpaired Student's *t* test was used for all analyses, within the GraphPad Prism4 software (GraphPad Software, Inc.).




FIG. 1. Deletion of *Cbp* in adult bone marrow affects lineage differentiation. (A) Genotyping of genomic DNA extracted from different tissues collected from *Cbp* wt or *Cbp* Mx animals 4 and 28 weeks after poly(I) · poly(C) (plpC) treatment demonstrated stable and nearly complete excision of *Cbp* in BM and PB. fl/fl and  $\Delta/\Delta$  represent *Cbp* floxed and null alleles, respectively. (B) Comparisons of BM cellularity (2 tibiae and 2 femurs) and spleen and liver weights between *Cbp* wt and *Cbp* Mx mice at 4 weeks and 28 weeks after poly(I) · poly(C) treatment. No differences were noted at either time point ( $n > 6$  for each genotype). (C) PB counts of *Cbp* wt and *Cbp* Mx over 28 weeks after poly(I) · poly(C) treatment. Deletion of *Cbp* led to a significant decrease in platelet numbers, while white blood cell (WBC) and hemoglobin (HGB) counts were not affected. (D) FACS analyses of PB, BM, and thymus cells from both genotypes at 4 and 28 weeks after poly(I) · poly(C) treatment. The bias toward myeloid lineages at the expense of lymphoid lineages became more pronounced at the 28-week time point. Results are shown as means  $\pm$  standard errors of the means ( $n > 15$  for each genotype at 4 weeks;  $n = 8$  for each genotype at 28 weeks). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ . DN, CD4 and CD8 double-negative cells.






FIG. 2. Modest alterations in the BM stem and progenitor compartments occur following *Cbp* deletion. (A) Representative FACS plots of BM compartments of *Cbp* wt and *Cbp* Mx mice 4 weeks after poly(I) · poly(C) treatment. (B) Graphs showing frequencies of LSK and progenitors and their subpopulations 4 weeks after poly(I) · poly(C)-induced *Cbp* excision. The ratio of myeloid progenitor frequency to LSK frequency is shown (with the ratio for *Cbp* wt mice normalized to 1). Results shown are means  $\pm$  standard errors of the means (SEM;  $n = 6$ ). (C) *Cbp*-deficient LSK cells do not mobilize to the spleen. Representative FACS plots show the LSK and progenitor compartments (gates on Lin<sup>-</sup>) in spleens from *Cbp* wt and *Cbp* Mx mice 4 weeks after poly(I) · poly(C) treatment. Data are shown as means  $\pm$  SEM ( $n = 4$ ). (D) Frequencies of BM subpopulations analyzed at 28 weeks post-poly(I) · poly(C) treatment. Results are means  $\pm$  SEM ( $n = 5$ ). \*,  $P < 0.05$ .




FIG. 3. *Cbp*-deficient BM cells are capable of BM reconstitution with reduced efficiency. (A) Noncompetitive transplantation. Representative FACS plots of PB cells from recipients transplanted with either *Cbp* wt or *Cbp* Mx cells (left panel). The right panel shows the contributions of *Cbp* wt and Mx cells to the recipient PB cells over 16 weeks following transplantation. Results are means  $\pm$  standard errors of the means (SEM;  $n = 10$  for each genotype). (B) Graph demonstrating the percentages of donor-derived B-cell (B220<sup>+</sup>), T-cell (CD3<sup>+</sup>), and granulocytic (Mac-1<sup>+</sup>Gr-1<sup>+</sup>) lineages in the PB of recipients at 16 weeks after the noncompetitive transplantation shown in panel A. (C) *Cbp*-deficient BM cells show no obvious defect in homing. Representative FACS plots are shown for BM cells from recipients transplanted with either *Cbp* wt or *Cbp* Mx BM cells that were labeled with CFSE prior to transplantation. The graphs on the right show percentages of total CFSE<sup>+</sup>, CFSE<sup>+</sup> progenitor, and

**Microarray data accession number.** Microarray and ChIP-seq data have been deposited into the NCBI Gene Expression Omnibus portal under the accession number GSE25274.

## RESULTS

### Deletion of *Cbp* alters hematopoietic lineage differentiation.


To study the role of *Cbp* in the adult hematopoietic system, we crossed *Cbp* conditional knockout mice (*Cbp* fl/fl) (18) with Mx-Cre transgenic mice (22), allowing Cre-mediated deletion of *Cbp* in the hematopoietic system upon injection of poly(I) · poly(C). Cre-mediated recombination at this genomic locus has been previously demonstrated to ablate *Cbp*, with no detectable *Cbp* protein expression (18, 19, 46). Efficient recombination was confirmed by PCR of genomic DNA at both 4 and 28 weeks post-poly(I) · poly(C) treatment (Fig. 1A). At both time points, no gross phenotypic abnormalities were observed in *Cbp* fl/fl; Mx-Cre<sup>+</sup> mice (referred to here as *Cbp* Mx) and *Cbp* fl/fl; Mx-Cre<sup>-</sup> littermate control mice (referred to here as *Cbp* wt). BM cellularity and spleen and liver weights were similar between the two genotypes (Fig. 1B). In serial measures of PB, no differences were observed in total white blood cell counts or hemoglobin levels between genotypes. However, we observed a significant decrease in platelet numbers in *Cbp* Mx mice, which was evident from as early as 4 weeks post-poly(I) · poly(C) treatment (Fig. 1C). Furthermore, at 4 weeks after *Cbp* deletion, flow cytometry analysis of PB showed a decline in the frequencies of B-cell (B220<sup>+</sup>) and T-cell (CD4<sup>+</sup>) lineages in *Cbp* Mx mice, as has been previously reported with excision of *Cbp* in later lymphoid compartments (19, 46). This decrease was accompanied by a concomitant increase in the percentage of myeloid cells (Mac-1<sup>+</sup> Gr-1<sup>+</sup>) (Fig. 1D). This differentiation bias toward the myeloid lineage became more marked over time, and by 28 weeks after poly(I) · poly(C) treatment the myeloid lineage was increased by around 3-fold in *Cbp* Mx mice, while both B- and T-cell lineages were decreased by 2.5-fold in comparison to *Cbp* wt mice (Fig. 1D). This pattern was recapitulated in BM cells at both time points, although it was less evident (Fig. 1D). It has previously been shown that deleting *Cbp* in thymocytes results in increased numbers of CD8 single-positive (SP) cells and decreased numbers of double-positive (DP) cells (18, 19). We observed a similar progressive phenotype at both time points. We and others have shown that poly(I) · poly(C)-induced Cre-mediated excision under the control of the Mx1 promoter is less efficient in thymocytes and spleen cells (Fig. 1A). Therefore, the initial phenotype we observed may have been diluted by the remaining *Cbp* fl/fl unexcised populations. Taken together, the above data suggest that deletion of *Cbp* in HSCs

biases toward myeloid differentiation, resulting in thrombocytopenia, lymphopenia, and myeloid cell expansion over time.

**Loss of *Cbp* alters the composition of the hematopoietic stem and progenitor compartment.** The differentiation defects observed in *Cbp* Mx mice may reflect possible alterations in the hematopoietic stem and progenitor cell (HSPC) compartment. We therefore examined the effect of *Cbp* deletion on the composition of HSPCs. At 4 weeks post-poly(I) · poly(C) treatment, we observed a mild decrease in the frequency of the HSC-enriched LSK population (Lin<sup>-</sup> c-Kit<sup>hi</sup> Sca1<sup>+</sup>) and a corresponding increased frequency of the myeloid progenitor compartment (Lin<sup>-</sup> IL-7R<sup>-</sup> c-Kit<sup>hi</sup> Sca1<sup>-</sup>) (Fig. 2A and B). When the ratio of progenitors to LSK cells was compared (Fig. 2B), there was over a 2-fold relative increase in the production of progenitors in *Cbp* Mx compared to wt mice. However, there was no significant difference in composition within the heterogeneous LSK compartment, as determined by the frequencies of the long-term HSC (LT-HSC; L<sup>-</sup> K<sup>+</sup> S<sup>+</sup> CD34<sup>-</sup> Flt3<sup>-</sup>), short-term HSC (ST-HSC; L<sup>-</sup> K<sup>+</sup> S<sup>+</sup> CD34<sup>+</sup> Flt3<sup>-</sup>), and lymphoid-primed multipotent progenitor compartments (LMPP; L<sup>-</sup> K<sup>+</sup> S<sup>+</sup> CD34<sup>+</sup> Flt3<sup>+</sup>) between *Cbp* Mx and wt mice (Fig. 2B). Within the myeloid progenitor compartment, no differences were noted in the frequency of the common myeloid progenitor (CMP) population (L<sup>-</sup> K<sup>+</sup> S<sup>-</sup> CD34<sup>+</sup> CD16/32<sup>int</sup>) between the two genotypes. However, a small increase in the granulocyte-monocyte progenitor (GMP; L<sup>-</sup> K<sup>+</sup> S<sup>-</sup> CD34<sup>+</sup> CD16/32<sup>hi</sup>) frequency, with a corresponding decrease in the megakaryocyte-erythroid progenitor cell (MEP; L<sup>-</sup> K<sup>+</sup> S<sup>-</sup> CD34<sup>-</sup> CD16/32<sup>lo</sup>) frequency was noted in *Cbp* Mx mice. Although nonsignificant, this difference may have contributed to the thrombocytopenia and myeloid lineage expansion observed in the PB over time. The common lymphoid progenitor (CLP; Lin<sup>-</sup> IL-7R<sup>+</sup> c-Kit<sup>int</sup> Sca1<sup>int</sup>) frequencies between the two genotypes were also similar.

The changes in the HSPC compartment in *Cbp* Mx mice were progressive, and at 28 weeks post-poly(I) · poly(C) treatment, the frequency of LSK in *Cbp* Mx mice was significantly reduced in comparison to *Cbp* wt mice (Fig. 2D). This reduction in LSK compartment size was not due to increased mobilization or redistribution of stem and progenitor cells to the spleen or PB (Fig. 2C and data not shown). Although the size of the *Cbp* Mx LSK population was reduced, the ratio of progenitor to LSK in *Cbp* Mx mice remained stable and was still greater than twice that of *Cbp* wt mice (Fig. 2D). This suggests that a bias directing HSC differentiation over self-renewal is maintained over time following *Cbp* deletion, which may, in turn, contribute to the gradual reduction of phenotypic HSCs.

CFSE<sup>+</sup> LSK cells of two genotypes detected in the recipient BM cells 24 h after transplantation. Data are means ± SEM (*n* = 6 for *Cbp* wt; *n* = 8 for *Cbp* Mx). (D) Competitive transplantation. Representative FACS analysis of PB cells from recipients transplanted with *Cbp* wt and Mx (test) and competitor cells at a 3:1 ratio (left panel). Graphs show the contributions of *Cbp* wt and Mx cells to the recipient PB reconstitution over a 22-week period following transplantation at a 1:1 ratio (middle panel) and 3:1 ratio (right panel). Results are means ± SEM (*n* = 5 for each genotype). \*, *P* < 0.05; \*\*, *P* < 0.01. (E) Deletion of *Cbp* in the BM niche does not significantly affect the reconstitution ability of wt donor BM cells. The graph shows the contributions of wt donor cells (45.1) to the PB cells of *Cbp* wt or *Cbp* Mx recipients over 20 weeks after transplantation (left panel). The right panel shows the percentages of different lineages derived from donor cells in the PB of these recipients at 20 weeks posttransplantation. Results are means ± SEM (*n* = 5 for each genotype).





***Chp*-deficient HSCs are capable of multilineage bone marrow reconstitution but engraft with decreased efficiency.** We next investigated if loss of *Chp* also affected normal HSC function. We first assessed the long-term multilineage bone marrow reconstitution ability of *Chp*-deficient BM cells in a noncompetitive transplantation experiment. One million unfractionated BM cells from either *Chp* Mx or *Chp* wt mice (CD45.2) were transplanted into lethally irradiated wild-type recipients (congenic CD45.1). Donor contribution to recipient PB reconstitution was monitored by flow cytometry at four weekly intervals for 16 weeks after transplantation. As shown in Fig. 3A, the degree of PB chimerism was similar between mice transplanted with *Chp* Mx and *Chp* wt BM cells. In addition, the frequencies of donor-derived B- and T-cell lineages in the PB of recipients transplanted with *Chp* Mx cells were reduced. This reduction in the lymphoid lineage resembled the phenotype observed after deleting *Chp* during homeostasis, suggesting that the differentiation defects caused by *Chp* deficiency are predominantly cell autonomous (Fig. 3B). In keeping with the normal reconstitution ability of *Chp* Mx cells in primary transplantation, no significant differences were observed in the homing abilities of progenitor or LSK cells between *Chp* wt and *Chp* Mx cells (Fig. 3C).

We next examined the relative BM reconstitution efficiency of *Chp*-deficient BM cells in a competitive setting. *Chp* Mx or wt whole BM cells (test; CD45.2) were mixed with normal wt competitor BM cells (competitor; CD45.1) at a ratio of 1:1 or 3:1 (test:competitor ratio) and subsequently transplanted into recipient mice (CD45.1/45.2). Analyses of PB chimerism in recipients showed a reduced contribution from *Chp* Mx cells, in comparison with *Chp* wt cells, at both ratios (Fig. 3D). Taken together, these data demonstrate that *Chp*-deficient BM cells are able to engraft and reconstitute lethally irradiated recipient mice; however, they do so with a reduced efficiency.

It has been reported that Cre expression under the Mx1 promoter is also induced in the HSC microenvironment (51). Moreover, it was shown recently that the *Chp*<sup>+/-</sup> microenvironment fails to maintain normal HSC function (53). To examine if deletion of *Chp* in the HSC microenvironment during homeostasis affects the reconstitution abilities of wt HSCs, we transplanted wt whole BM cells (CD45.1) into lethally irradiated *Chp* wt or *Chp* Mx recipients (CD45.2) 4 weeks after poly(I) · poly(C) treatment. No difference in the levels of PB chimerism or multilineage reconstitution could be detected over 20 weeks posttransplantation between recipients of the two genotypes (Fig. 3E). Although it is possible that excision under the control of the Mx1 promoter may not totally delete


*Chp* in all critical niche compartments, these data suggest that deletion of *Chp* in the HSC niche during homeostasis has little effect on the engraftment and long-term multilineage reconstitution of donor cells.

**Loss of *Chp* leads to exhaustion of HSCs upon serial transplantation.** We further examined the effect of *Chp* deficiency on long-term HSC self-renewal under the replicative stress of serial transplantation. Secondary transplantation was performed 16 weeks after the initial transplantation, whereby 10<sup>6</sup> total BM mononuclear cells were harvested from the primary recipients and transplanted into lethally irradiated secondary recipients. This process was iteratively repeated into tertiary recipients after another 16 weeks. As previously mentioned, *Chp* Mx BM cells were able to engraft primary recipients to a similar level as *Chp* wt cells (Fig. 3A). However, in the secondary recipients the contribution of *Chp* Mx donor cells to total PB, as well as to individual lineages, was dramatically decreased compared to *Chp* wt cells (Fig. 4A). In the tertiary transplant recipients, *Chp* Mx cells were virtually undetectable, while *Chp* wt cells still demonstrated a high level of engraftment.

Consistent with the results for PB, *Chp* Mx cells were able to reconstitute total BM cells as well as the HSPCs in the primary recipients. In the secondary recipients, *Chp* Mx donor cells showed decreased contributions to total BM cells and HSPCs (Fig. 4B, top and middle panels). Notably, we observed a significant reduction in the percentages of donor-derived LSK in both primary and secondary recipients of *Chp* Mx compared to *Chp* wt cells (Fig. 4B, lower panel). This recapitulates the reduced LSK frequency observed in *Chp* Mx mice after poly(I) · poly(C) treatment (Fig. 2B and D), further indicating a cell-autonomous defect in stem cell self-renewal. In the tertiary recipients, virtually no evidence of *Chp* Mx contribution to hematopoiesis was seen, while *Chp* wt cells still significantly contributed to the total BM, LSK, and progenitor compartments (Fig. 4B). These data demonstrate that, under replicative stress, *Chp*-deficient HSCs are exhausted, suggesting an inability to sufficiently maintain the HSC pool through impaired self-renewal.

**Aberrant regulation of the cell cycle and increased apoptosis contribute to HSC exhaustion in *Chp*-deficient mice.** To further investigate the cellular nature of our HSC exhaustion phenotype, we next assessed the cell cycle and apoptotic characteristics of *Chp*-deficient HSPCs 4 weeks after poly(I) · poly(C) treatment. At 4 weeks after poly(I) · poly(C) administration, we detected a mild but statistically significant increase in apoptosis in *Chp* Mx LSK cells, but not in the

FIG. 4. Progressive exhaustion of *Chp*-deficient HSCs under replicative stress. (A) The upper graphs show the contributions of *Chp* wt and Mx cells to reconstitution of the recipient PB cells over 16 weeks following the secondary (2nd) and tertiary (3rd) transplantations. The *Chp* Mx contribution was dramatically decreased in the secondary transplantation and extinguished in the tertiary. Contributions to different lineages of PB cells are also shown (lower panels). Results are means  $\pm$  standard errors of the means (SEM; secondary transplantation,  $n = 10$  for each genotype; tertiary transplantation,  $n = 6$  for each genotype). \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ . (B) FACS analyses of BM chimerism in the primary, secondary, and tertiary recipients. The upper panels show the contribution of donor-derived cells (CD45.2) to total BM cellularity. The middle panels show the contribution of CD45.2 cells to the LSK and progenitor compartments (HSPCs). The lower panel shows the frequencies of donor-derived LSK populations in the primary and secondary recipients of *Chp* wt or *Chp* Mx cells. Similar to the result for PB cells, the contribution of the CD45.2 *Chp* Mx cells to BM cellularity and HSPC dramatically decreased with successive transplantations, indicating a severe defect in HSC self-renewal under replicative stress. All results are shown as means  $\pm$  SEM ( $n \geq 5$  for each genotype). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .



progenitor compartment, as assessed by staining with annexin V/7-AAD (Fig. 5A). *In vivo* BrdU incorporation showed no obvious differences in the proportions of either LSK or progenitors in S or G<sub>2</sub>/M phases in the absence of *Cbp* (Fig. 5B), suggesting that loss of *Cbp* has no effect on cycling of stem and progenitor cells. However, a noticeable increase in cells in G<sub>0</sub>/G<sub>1</sub> in both LSK and progenitor compartments prompted us to further assess quiescent and cycling states, based on the intracellular expression of ki-67 and 7-AAD staining (Fig. 5C). Surprisingly, the LSK population from *Cbp* Mx mice demonstrated an increase in quiescent (G<sub>0</sub>) cells and a concomitant decrease in the G<sub>1</sub> fraction. An increased proportion of quiescent cells was also demonstrated in the progenitor compartment of *Cbp* Mx mice. In consonance with the BrdU analysis, no change in the proportion of HSPCs in S/G<sub>2</sub>/M was observed between *Cbp* Mx and *Cbp* wt animals (Fig. 5C), confirming that deletion of *Cbp* had no obvious effect on stem and progenitor cells that were able to enter the cell cycle. Taken together, the above data demonstrated that deletion of *Cbp* leads to an accumulation of stem and progenitor cells in the quiescent state and an increase in apoptosis within the LSK compartment during adult homeostasis. These cellular characteristics further contribute to the HSC exhaustion phenotype we describe.

**The *Cbp*-deficient HSC phenotype is exacerbated by *in vivo* 5-FU treatment.** To gain further insights into the impaired self-renewal of *Cbp*-deficient HSCs under replicative stress, we challenged *Cbp* wt and *Cbp* Mx mice with one dose of 5-FU, 4 weeks after *Cbp* deletion, and monitored the recovery of the HSPC compartments as well as the cell cycle characteristics of these compartments. 5-FU treatment eliminated any cycling hematopoietic cells and therefore induced HSCs into the cell cycle to replenish the hematopoietic system. Ten days after 5-FU treatment, the LSK frequency in *Cbp* Mx mice was significantly lower than in *Cbp* wt mice (Fig. 5D). We also observed a marked reduction in the frequency of LT-HSCs and ST-HSCs, with a concomitant increase in MPP frequency in *Cbp* Mx mice, changes not apparent during homeostasis (Fig. 2B). Although total progenitor frequency was not altered, there was a significant increase in the proportion of GMP and a concomitant significant decrease in the proportion of MEP when *Cbp* Mx mice were compared to *Cbp* wt mice (see Fig. S1 in our supplemental material posted at [http://hscl.cimr.cam.ac.uk/genomic\\_supplementary.html](http://hscl.cimr.cam.ac.uk/genomic_supplementary.html)). These data show an accen-

tuation of the homeostatic phenotype and further demonstrate preferential differentiation and granulocyte/monocyte production (Fig. 5D). In addition, when we examined the cell cycle status of LSK cells after 5-FU treatment, there was a significant decrease in S/G<sub>2</sub>/M cycling LSK cells. These data together further suggest that under replicative stress, *Cbp*-excised LSK cells undergo increased differentiation and reduced cell cycle progression, which together lead to exhaustion of HSCs.

**Gene expression analysis identified candidate HSC pathways regulated by *Cbp*.** *Cbp* is a global transcriptional coactivator, interacting with numerous transcription factors, including important hematopoietic regulators like Gata-1, Gata-2, Runx2, and Rb1 (3). We therefore predicted that its loss would result in an alteration of multiple, rather than single, transcriptional programs. To identify alterations in global gene expression and the molecular mechanisms underlying the stem cell and cell cycle defects, we performed microarray analysis in the LSK populations of *Cbp* wt and *Cbp* Mx mice, a population enriched for hematopoietic stem cells. The analysis was performed at 4 weeks after *Cbp* deletion, the time point at which we had already documented changes in differentiation, apoptosis, and the cell cycle. Microarray analysis identified 341 unique transcripts (187 upregulated and 154 downregulated) differentially expressed ( $P < 0.05$ ) between *Cbp* Mx and wt LSK for which the expression level varied by  $\pm 1.4$ -fold ( $\log_2, > \pm 0.5$ ) (Fig. 6A; see also our supplemental Table S1 at [http://hscl.cimr.cam.ac.uk/genomic\\_supplementary.html](http://hscl.cimr.cam.ac.uk/genomic_supplementary.html)). The overall change in gene expression level was modest, with only around 30 genes showing greater-than-2-fold differences in expression level. However, consistent with our data, others have reported similar modest alterations in gene expression after deleting *Cbp* in mature T and B cells, suggesting a more subtle modulation of transcript levels upon *Cbp* loss (18, 46). Genes differentially expressed in LSK included genes implicated in the phenotypic abnormalities demonstrated in our *Cbp* Mx mice: abnormal cell cycle control [upregulation of *Gfi1b* and *Cxcl12*; downregulation of *Ccnd1*, *Ccnd2*, *Cdkn1a(p21)*, *Rb1*, and *Mcm7*], and altered differentiation (upregulation of myeloid differentiation genes, including *Mpo*, *Ela2*, *Cd16*, and *Ctsg*; downregulation of lymphoid genes, including *Rag1*) (Fig. 6A). The differential expression of a subset of these genes was confirmed by qRT-PCR (Fig. 6B).

In order to gain further insights into pathways and cellular processes altered by loss of *Cbp*, we next performed GSEA

**FIG. 5.** *Cbp*-deficient LSK and progenitor cells demonstrated alterations of quiescence and apoptosis. (A) Representative FACS plots of annexin V/7-AAD staining on LSK and progenitor cells from *Cbp* wt and *Cbp* Mx mice. Percentages of apoptotic LSK and progenitor cells (annexin V<sup>+</sup> 7-AAD<sup>+</sup>) from *Cbp* wt and *Cbp* Mx animals show increased apoptosis in LSK but not progenitors from *Cbp* Mx mice. Results shown are means  $\pm$  standard errors of the means (SEM;  $n = 8$  for *Cbp* wt;  $n = 9$  for *Cbp* Mx). \*,  $P < 0.05$ . (B) Both *Cbp* wt and Mx mice were injected with 1 mg of BrdU 24 h before analysis. Representative FACS plots show cell cycle distributions of LSK and progenitors in *Cbp* wt and Mx mice. DNA content was stained with 7-AAD. Graphs show the percentages of cells in the different cell cycle phases. The proportions of LSK and progenitor cells in S or G<sub>2</sub>/M were similar between *Cbp* wt and Mx mice, suggesting that deletion of *Cbp* does not affect the cycling stem and progenitor cells. Data are mean  $\pm$  SEM ( $n = 4$  for *Cbp* wt;  $n = 5$  for *Cbp* Mx). (C) The cell cycle status of LSK and progenitor cells was determined by the combined expression of the proliferation marker ki67 and the DNA-staining dye 7-AAD. Representative FACS plots from both *Cbp* wt and *Cbp* Mx mice are shown. Graphs show the proportions of LSK and progenitor cells at different stages of the cell cycle. Both *Cbp* Mx LSK and progenitors demonstrated an increase in quiescent (G<sub>0</sub>) fractions. Results are shown as means  $\pm$  SEM ( $n = 11$  for *Cbp* wt;  $n = 14$  for *Cbp* Mx). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ . (D) Analysis of the LSK compartment under stress conditions. *Cbp* wt or Mx mice were treated with one dose of 5-FU, 4 weeks after poly(I) · poly(C) treatment. Graphs show the frequencies of LSK and its subpopulations 10 days after 5-FU treatment (left and middle panels). The cell cycle status of the LSK compartment was determined based on the expression of Ki-67 and staining with the DNA dye 7-AAD (right panel). Results are means  $\pm$  SEM ( $N > 6$ ). \*,  $P < 0.05$ ; \*\*\*,  $P < 0.001$ .




FIG. 6. Microarray analysis identified candidate genes regulated by Cbp. (A) Heat map showing probes differentially expressed more than 1.4-fold (up- or downregulated) between *Cbp* wt and *Cbp* Mx LSK cells ( $P < 0.05$ ). Selected genes, either up- or downregulated and proposed to contribute to our cellular phenotypes, are listed to the right of the heat map. (B) qRT-PCR analysis for selected genes confirmed differential expression levels for the majority of genes between *Cbp* wt and Mx LSK cells. Results are from 3 individual samples from each genotype and are shown as means  $\pm$  standard errors of the means. *Cbp* wt samples were averaged and normalized to 1. (C) Representative GSEA, demonstrating that both Heptad-bound genes (right panel) and genes downregulated in quiescent versus dividing HSCs (left panel) are strongly enriched within genes downregulated in *Cbp*<sup>-/-</sup> LSK (nominal  $P$  value,  $<0.001$ ).

(<http://www.broadinstitute.org/gsea>) to compare our gene expression profile with all published curated gene sets (c2, version 3). Among 1,978 unselected gene sets analyzed, 22 gene sets were enriched in genes upregulated in *Cbp*<sup>-/-</sup> LSK cells, while 79 showed significant enrichment in genes downregulated in *Cbp*<sup>-/-</sup> LSK cells (nominal  $P$  value,  $<0.001$ ). Interestingly, the latter group included gene sets with genes downregulated in quiescent versus dividing human CD34<sup>+</sup> hematopoietic cells as well as genes related to the G<sub>1</sub> cell cycle checkpoint (Fig. 6C; see also Table S2 at [http://hscl.cimr.cam.ac.uk/genomic\\_supplementary.html](http://hscl.cimr.cam.ac.uk/genomic_supplementary.html)), in agreement with the cell cycle defect observed upon *Cbp* deletion. In addition, we recently identified 927 target genes bound by 7 major hematopoietic transcriptional regulators (Scf/Ly11/Gata2/Runx1/Lmo2/Fli-1/Erg) in a hematopoietic stem and progenitor system (45). This Heptad target gene set is highly enriched for

genes specifically expressed in HSCs. By GSEA, the Heptad gene set showed a strong correlation with genes downregulated in *Cbp*-deficient LSK cells (Fig. 6C; see also supplemental Table S3 at [http://hscl.cimr.cam.ac.uk/genomic\\_supplementary.html](http://hscl.cimr.cam.ac.uk/genomic_supplementary.html)). These data suggest that loss of *Cbp* may alter HSC function through decreased expression of critical HSC-specific genes regulated by these core hematopoietic transcription factors.

**Genome-wide analysis of Cbp occupancy identifies the HSC-specific transcriptional network coordinated by Cbp.** Cbp executes its function by interacting with a number of transcriptional regulators. The significant enrichment of Heptad target genes in genes downregulated after loss of Cbp suggests that Cbp may contribute to the regulatory network controlling normal hematopoiesis. We therefore performed ChIP-seq analysis in HPC-BM cells to identify the putative HSC transcriptional



network coordinated by Cbp. The small available number of LSK cells precluded ChIP-seq analysis within this compartment. The immortalized HPC-BM cell line retains the HSC characteristics of self-renewal and multilineage potential *in vivo* without leukemic transformation (33), thus providing a surrogate HSPC transcriptional environment. Analyses of Cbp ChIP-seq data in comparison with control IgG data identified a total of 3,228 peaks associated with 2,395 genes, with 1,456 peaks (45.1%) located in the intergenic regions, 671 peaks (20.8%) in the promoter regions, and 1,101 peaks (34.1%) in the intragenic regions (Fig. 7A; see also supplemental Table S4 at [http://hscl.cimr.cam.ac.uk/genomic\\_supplementary.html](http://hscl.cimr.cam.ac.uk/genomic_supplementary.html)). GSEA, using all genes bound by Cbp as the enquiry gene set, showed that these potential Cbp target genes were significantly enriched ( $P < 0.001$ ) in genes downregulated, but not those upregulated, in *Cbp*-deficient cells, an observation in agreement with the well-recognized function of Cbp as a transcriptional coactivator (Fig. 7B; see also supplemental Table S5 at [http://hscl.cimr.cam.ac.uk/genomic\\_supplementary.html](http://hscl.cimr.cam.ac.uk/genomic_supplementary.html)). Enrichment of binding at selected loci was confirmed by individual ChIP-qPCR (Fig. 7C). Among genes bound by Cbp were members of the Krüppel-like factor family (*Klf2*, *Klf10*, and *Klf13*), *Runx1*, *Gfi1b*, and *Gata2* (Fig. 7A; see also supplemental Table S4 at [http://hscl.cimr.cam.ac.uk/genomic\\_supplementary.html](http://hscl.cimr.cam.ac.uk/genomic_supplementary.html)). These genes have important functions in hematopoiesis, cell cycle regulation, and HSC self-renewal, further implicating Cbp function in the regulation of these cellular processes by coordinating critical transcription factors.

Heptad target genes were strongly correlated with genes downregulated following *Cbp* deletion. We therefore investigated any common genes bound by both Cbp and the Heptad factors. When we compared 2,395 genes bound by Cbp with the 927 genes combinatorially bound by Heptad factors, there was a highly significant overlap of 324 genes ( $P = 6.428 \times 10^{-85}$ ) (Fig. 7D; see also supplemental Table S6 at [http://hscl.cimr.cam.ac.uk/genomic\\_supplementary.html](http://hscl.cimr.cam.ac.uk/genomic_supplementary.html)), implicating Cbp as a component of the hematopoietic transcriptional network regulated by the Heptad factors. Finally, *de novo* motif analysis of all peaks bound by Cbp demonstrated enrichment for *Ets*, *Klf*, and *Creb1* consensus sequences (Fig. 7E). This suggests that the transcriptional activity of *Ets* (including the Heptad members *Fli1* and *Erg*), *Klf* family members, and *Creb1*, which are all known to be involved in stem cell self-renewal, are coordinated by Cbp in the regulation of normal HSC function.

## DISCUSSION


Hematopoietic stem cells have unique properties of long-term self-renewal and multilineage differentiation, which ensure the life-long production of all terminal hematopoietic lineages. To maintain the HSC pool and prevent HSC exhaustion, HSCs must precisely regulate often-antagonistic cellular processes, such as quiescence, proliferation, apoptosis, self-renewal, and differentiation, through tightly controlled transcriptional programs (32, 54). Based on our combination of cellular and molecular analyses, we suggest that the transcriptional coactivator *Cbp* regulates adult HSC homeostasis (Fig. 8) through the orchestration of cell fate decisions by the combinatorial actions of specific transcription factors.

Following loss of *Cbp* in the adult HSC compartment, the

size of the LSK compartment gradually decreased, with a concomitant increase in the myeloid progenitor compartment. This was accompanied by a fixed, over-2-fold increase in the progenitor-to-LSK ratio in *Cbp* Mx mice, indicating an altered balance between HSC self-renewal and myeloid differentiation with a bias toward the latter. In addition, gene expression analysis showed increased expression levels of myeloid differentiation-related transcripts, including *Mpo*, *Ela2*, and *Cd16*, and decreased lymphoid-related genes, including *Rag1* in *Cbp*<sup>-/-</sup> LSK cells, thus providing molecular evidence for myeloid priming at the stem cell level following *Cbp* deletion. These data provide the first evidence that loss of *Cbp* in adult HSCs selectively increases myeloid over lymphoid lineage production. It is possible that *Cbp* deficiency in more-differentiated compartments also contributes to the differentiation defects observed, as has been demonstrated in other studies during lymphoid differentiation (19, 46).

*Cbp* has been shown to play a critical role during HSC specification and early embryonic development (23, 29, 30, 41, 47). Our phenotypic and functional data, in contrast, demonstrate a relatively milder defect upon loss of *Cbp*. *Cbp*-deficient HSCs were able to repopulate lethally irradiated recipients, albeit with reduced efficiency. These data are reminiscent of the relative subtle defects in HSC function after homeostatic loss of critical developmental regulators of hematopoiesis, such as *Scl* and *Runx1* (16, 26). We speculate that loss of *Cbp* is compensated for by the cellular reserve of the adult HSC pool prior to deletion and a degree of functional redundancy with the paralogous coactivator p300 at the molecular level. Nevertheless, under the replicative stress of serial transplantation, and to a lesser extent following *in vivo* 5-FU treatment, *Cbp*-excised BM cells demonstrated an obvious inability to maintain the stem cell pool, indicating a marked and predominantly cell-autonomous defect in HSC self-renewal. The self-renewal potential is determined by the size of the stem cell pool, which is in turn influenced by the rate of loss of HSCs through apoptosis or differentiation and by the proliferative state of this pool. In addition to preferential differentiation of the HSC compartment, we demonstrated an increase in apoptosis and quiescence within the *Cbp*<sup>-/-</sup> LSK compartment, which cumulatively led to stem cell exhaustion (Fig. 8). These results provide the first detailed mechanistic data to account for the function of *Cbp* in adult HSC homeostasis and demonstrate that *Cbp* plays a role in the regulation of cellular fate decisions in adult HSCs.

Precise regulation of the cell cycle is critical for normal HSC function. Loss of function of many critical genes has been shown to cause a stem cell defect through an alteration of the balance between quiescence and cell cycle entry (14, 31). Previously, however, loss of stem cell function following deletion of a critical regulator has been almost uniformly accompanied by loss of quiescence and an increase in cell cycle progression. In contrast, our data demonstrated the opposite and corroborated a recent report whereby stabilization of Hif-1 $\alpha$  through biallelic loss of the E3 ubiquitin ligase von Hippel-Lindau (VHL) protein also resulted in increased quiescence, a decrease in cell cycle entry, and a loss of HSC number and function (40). These data demonstrated that an increase in HSC quiescence may actually be detrimental to HSC function rather than protective, as has been seen following deletion of






FIG. 8. *Cbp* regulates HSC fate decisions. The schematic diagram summarizes the role of *Cbp* in the maintenance of the HSC pool. The HSC pool is normally maintained through self-renewal, which reflects an ordered balance of proliferation and differentiation of HSCs with minimal cell death (left panel). In contrast, in *Cbp*<sup>-/-</sup> HSCs (right panel), these critical cell fate decisions are altered, leading to an increase in quiescence and apoptosis, to preferential differentiation, and ultimately HSC exhaustion through decreased self-renewal (red arrows). Based on our integrated genomic analyses, we propose that this occurs through the inability of *Cbp*<sup>-/-</sup> HSCs to properly coordinate the transcriptional programs necessary to regulate these cell fate decisions.

the *Mef/Elf4* transcription factor (24), and the data further enforce the notion that exquisite control of the cell cycle is critical during adult HSC homeostasis. The mechanisms that regulate quiescence in stem cells are still poorly understood. However, a complex interplay between signals transduced from the stem cell niche through ligand-cell surface receptor modules, such as the *Cxcl12-Cxcr4* (28) and *Tpo-cMpl* (49) axes, appear to control cell cycle entry and progression through intrinsic factors, such as *Pten* (48, 50), *Gfi1/Gfi1b* (15, 20), *Cdkn1a/p21* (6), and *Foxo* transcription factors (27, 42). We identified altered expression levels of many genes implicated in cell cycle control following *Cbp* loss in the LSK population enriched for hematopoietic stem cells (Fig. 6; see also Supplemental Table S1 at [http://hscl.cimr.cam.ac.uk/genomic\\_supplementary.html](http://hscl.cimr.cam.ac.uk/genomic_supplementary.html)), and it is likely that the cell cycle phenotype observed is a composite of these net transcriptional changes. For example, an alteration of the balance of cell cycle entry toward quiescence may be explained, at least in part, by an upregulation of *Cxcl12* and *Gfi1b*, both positive regulators of quiescence, with *Cxcl12* potentially forming an autocrine loop with *Cxcr4* in HSCs. Although another positive regulator, *Cdkn1a*, was actually downregulated in this same analysis, these findings along with a loss of negative regulation of *Foxo* factors through *Cbp*-mediated acetylation (44) would be predicted to favor an increase of quiescence in HSCs.

In this study, we have provided the first genome-wide analysis of *Cbp* occupancy in the hematopoietic system and demonstrated that *Cbp* integrates into an HSC-specific transcriptional network (45). This “Heptad network” has been reconstructed from combinatorial genome-wide binding patterns in a stem cell model cell line and comprises seven transcription factors well known to regulate stem cell quiescence, self-renewal, and differentiation. Comparison of the combinatorial binding patterns of these Heptad factors revealed a highly significant overlap with genes downregulated upon *Cbp* loss in LSK cells and with our own *Cbp* genome-wide binding pattern. Furthermore, genome-wide motif analysis of *Cbp*-binding peaks revealed enrichment for consensus Ets binding sites (*Fli1* and *Erg* are Ets family members). In addition, it is likely that *Cbp* coordinates additional transcriptional networks, as was evidenced by the motif enrichment for *Klf* and *Creb1* consensus sequences at *Cbp*-bound regions. Krüppel-like factor family members have been implicated in ES cell self-renewal, and *Klf4* is one of the four transcription factors required to reverse the highly differentiated state of somatic cells back to pluripotency (17, 38). *Creb1/CREB1* has been demonstrated to be a critical regulator of both normal hematopoiesis and leukemogenesis (5, 36). We propose that *Cbp* may further regulate the function of these networks at a subset of loci through acetylation of histone and nonhistone proteins

FIG. 7. ChIP-seq analysis identified the potential hematopoietic transcription network coordinated by *Cbp*. (A) Representative ChIP-seq data, showing *Cbp* binding at the *Klf2* and *Runx1* loci. The scale of enrichment is shown to the left of the data. The relationships of a gene to the peaks and the genomic scale are shown below and above the individual tracks, respectively. (B) GSEA plot demonstrating that genes bound by *Cbp* are strongly correlated with genes downregulated in *Cbp*<sup>-/-</sup> LSK. (C) Real-time PCR verification of several genomic loci. The *MyoD* promoter region was used as a negative binding region. Results are from 2 individual PCR assays. Data are presented as means  $\pm$  standard errors of the means. (D) Significant overlaps between genes bound by *Cbp* and the Heptad factors. The UCSC Genome Browser tracks demonstrate an example of *Cbp* binding at the *Runx1* intragenic region, which is also bound by the Heptad factors (black box). (E) A *de novo* motif discovery identified Ets, *Klf*, and *Creb1* motifs preferentially bound by *Cbp*.

(including Heptad members, such as Runx1 and Gata2) (13, 21) and/or by providing a protein scaffold for nucleation of network members and other high-order transcriptional complex members.

Taken together, our data demonstrate that *Cbp* orchestrates multiple critical cell fate decisions in HSCs and suggest that this occurs through the ability of *Cbp* to integrate the transcriptional programs that mediate these decisions. In this respect, it behaves similarly to another epigenetic regulator, *Dnmt1*, to preserve HSC multipotency and self-renewal through control of critical transcriptional programs (4, 43), a finding that further underlines the role of epigenetic modulation as an important layer of control in HSC regulation.

#### ACKNOWLEDGMENTS

We thank Katrin Ottersbach and David Kent for helpful discussions.

Work in our lab is sponsored by CRUK, Medical Research Council (MRC; United Kingdom), Leukemia and Lymphoma Research (United Kingdom), The Wellcome Trust, the Leukemia and Lymphoma Society of America, and the NIHR Cambridge Biomedical Research Centre. B.H. is funded by an MRC (United Kingdom) senior clinical research fellowship, and M.A.D. is supported by a Wellcome-Beit intermediate clinical fellowship.

#### REFERENCES

- Bailey, T. L., and C. Elkan. 1994. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. *Proc. Int. Conf. Intell. Syst. Mol. Biol.* 2:28–36.
- Bannister, A. J., and T. Kouzarides. 1996. The CBP activator is a histone acetyltransferase. *Nature* 384:641–643.
- Bedford, D. C., L. H. Kasper, T. Fukuyama, and P. K. Brindle. 2010. Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases. *Epigenetics* 5:9–15.
- Bröske, A.-M., et al. 2009. DNA methylation protects hematopoietic stem cell multipotency from myeloid restriction. *Nat. Genet.* 41:1207–1215.
- Cheng, J. C., et al. 2008. CREB is a critical regulator of normal hematopoiesis and leukemogenesis. *Blood* 111:1182–1192.
- Cheng, T., et al. 2000. Hematopoietic stem cell quiescence maintained by p21<sup>cip1/waf1</sup>. *Science* 287:1804–1808.
- Crowley, J. A., Y. Wang, A. P. Rapoport, and Y. Ning. 2005. Detection of MOZ-CBP fusion in acute myeloid leukemia with 8;16 translocation. *Leukemia* 19:2344–2345.
- Dawson, M. A., et al. 2009. JAK2 phosphorylates histone H3Y41 and excludes HP1 $\alpha$  from chromatin. *Nature* 461:819–822.
- Du, P., W. A. Kibbe, and S. M. Lin. 2008. lumi: a pipeline for processing Illumina microarray. *Bioinformatics* 24:1547–1548.
- Goodman, R. H., and S. Smolik. 2000. CBP/p300 in cell growth, transformation, and development. *Genes Dev.* 14:1553–1577.
- Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. *Cell* 90:595–606.
- Gupta, S., J. A. Stamatoyannopoulos, T. L. Bailey, and W. S. Noble. 2007. Quantifying similarity between motifs. *Genome Biol.* 8:R24.
- Hayakawa, F., et al. 2004. Functional regulation of GATA-2 by acetylation. *J. Leukoc. Biol.* 75:529–540.
- He, S., D. Nakada, and S. J. Morrison. 2009. Mechanisms of stem cell self-renewal. *Annu. Rev. Cell Dev. Biol.* 25:377–406.
- Hock, H., et al. 2004. Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. *Nature* 431:1002–1007.
- Ichikawa, M., et al. 2004. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. *Nat. Med.* 10:299–304.
- Jiang, J., et al. 2008. A core Klf circuitry regulates self-renewal of embryonic stem cells. *Nat. Cell Biol.* 10:353–360.
- Kang-Decker, N., et al. 2004. Loss of CBP causes T cell lymphomagenesis in synergy with p27<sup>Kip1</sup> insufficiency. *Cancer Cell* 5:177–189.
- Kasper, L. H., et al. 2006. Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. *Mol. Cell. Biol.* 26:789–809.
- Khandanpour, C., et al. 2010. Evidence that growth factor independence 1b (Gfi1b) regulates dormancy and peripheral blood mobilization of hematopoietic stem cells. *Blood* 116:5149–5161.
- Kitabayashi, I., Y. Aikawa, L. A. Nguyen, A. Yokoyama, and M. Ohki. 2001. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. *EMBO J.* 20:7184–7196.
- Kuhn, R., F. Schwenk, M. Aguet, and K. Rajewsky. 1995. Inducible gene targeting in mice. *Science* 269:1427.
- Kung, A. L., et al. 2000. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. *Genes Dev.* 14:272–277.
- Lacorazza, H. D., et al. 2006. The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells. *Cancer Cell* 9:175–187.
- Lin, S. M., P. Du, W. Huber, and W. A. Kibbe. 2008. Model-based variance-stabilizing transformation for Illumina microarray data. *Nucleic Acids Res.* 36:e11.
- Mikkola, H. K. A., et al. 2003. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. *Nature* 421:547–551.
- Miyamoto, K., et al. 2007. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. *Cell Stem Cell* 1:101–112.
- Nie, Y., Y.-C. Han, and Y.-R. Zou. 2008. CXCR4 is required for the quiescence of primitive hematopoietic cells. *J. Exp. Med.* 205:777–783.
- Oike, Y., et al. 1999. Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. *Hum. Mol. Genet.* 8:387–396.
- Oike, Y., et al. 1999. Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. *Blood* 93:2771–2779.
- Orford, K. W., and D. T. Scadden. 2008. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. *Nat. Rev. Genet.* 9:115–128.
- Orkin, S. H., and L. I. Zon. 2008. Hematopoiesis: an evolving paradigm for stem cell biology. *Cell* 132:631–644.
- Pinto do Ó, P., K. Richter, and L. Carlsson. 2002. Hematopoietic progenitor/stem cells immortalized by Lhx2 generate functional hematopoietic cells in vivo. *Blood* 99:3939–3946.
- Rebel, V. I., et al. 2002. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. *Proc. Natl. Acad. Sci. U. S. A.* 99:14789–14794.
- Roelfsema, J. H., and D. J. M. Peters. 2007. Rubinstein-Taybi syndrome: clinical and molecular overview. *Expert Rev. Mol. Med.* 9:1–16.
- Shankar, D. B., et al. 2005. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. *Cancer Cell* 7:351–362.
- Subramanian, A., et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* 102:15545–15550.
- Takahashi, K., and S. Yamanaka. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126:663–676.
- Taki, T., M. Sako, M. Tsuchida, and Y. Hayashi. 1997. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. *Blood* 89:3945–3950.
- Takubo, K., et al. 2010. Regulation of the HIF-1 $\alpha$  level is essential for hematopoietic stem cells. *Cell Stem Cell* 7:391–402.
- Tanaka, Y., et al. 2000. Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein. *Mech. Dev.* 95:133–145.
- Tothova, Z., et al. 2007. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. *Cell* 128:325–339.
- Trowbridge, J. J., J. W. Snow, J. Kim, and S. H. Orkin. 2009. DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. *Cell Stem Cell* 5:442–449.
- Vogt, P. K., H. Jiang, and M. Aoki. 2005. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. *Cell Cycle* 4:908–913.
- Wilson, N. K., et al. 2010. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. *Cell Stem Cell* 7:532–544.
- Xu, W., et al. 2006. Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells. *Blood* 107:4407–4416.
- Yao, T. P., et al. 1998. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. *Cell* 93:361–372.
- Yilmaz, O. H., et al. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. *Nature* 441:475–482.
- Yoshihara, H., et al. 2007. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. *Cell Stem Cell* 1:685–697.
- Zhang, J., et al. 2006. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. *Nature* 441:518–522.
- Zhang, J., et al. 2003. Identification of the haematopoietic stem cell niche and control of the niche size. *Nature* 425:836–841.
- Zhang, Y., et al. 2008. Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* 9:R137.
- Zimmer, S. N., et al. 2011. Crebbp haploinsufficiency in mice alters the bone marrow microenvironment leading to loss of stem cells and excessive myelopoiesis. *Blood* 118:69–79.
- Zon, L. I. 2008. Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. *Nature* 453:306–313.